Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verutex, Eritex, and Fisiogel for Tarceva-associated rash in NSCLC
NCT00718315Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2009
- Primary completion
- Jun 2012
- Modality
- Transdermal Patches, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fusidic acid, erythromycin, Physiogel in drug eruption, sponsored by Roche. Started Apr 2009; status: completed.
02
Drugs
fusidic aciderythromycinPhysiogel
03
Conditions
drug eruption
Beyond the preview
Go deeper on NCT00718315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718315.